hit counter
Calithera Biosciences, Inc. (CALA) Stock News Sentiment & Price - Sentifly
CALA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Calithera Biosciences, Inc. (CALA)

USA
Biotechnology
NASDAQ
CALA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CALA Latest news
GlobeNewsWire
Neutral
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021
2021-10-21 08:00

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company's investigational arginase inhibitor for the treatment of cystic fibrosis (CF), will be shared in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place virtually November 2-5, 2021.

Benzinga
Positive
Calithera Buys Two Oncology Candidates From Takeda For $45M
2021-10-19 06:51

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock.

GlobeNewsWire
Neutral
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
2021-10-18 16:07

-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company's precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022 --

GlobeNewsWire
Neutral
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer
2021-09-08 07:00

KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway

GlobeNewsWire
Neutral
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
2021-09-02 07:00

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its participation in two upcoming virtual healthcare investor conferences.

Seeking Alpha
Neutral
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2021 Results - Earnings Call Transcript
2021-08-08 04:39

Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
2021-08-05 16:05

-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021--

Seeking Alpha
Neutral
The Upcoming Calithera Cystic Fibrosis Data Could Be Significant
2021-08-03 02:05

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

GlobeNewsWire
Neutral
Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021-07-29 07:00

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company's second quarter 2021 financial results will be released on Thursday, August 5, 2021. Company management will host a conference call on Thursday, August 5, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Zacks Investment Research
Positive
Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options
2021-07-12 10:06

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

Loading more news...